Dror Harats News Today

NTBL | Complete Notable Labs Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval $24.3 million in cash and cash equivalents as of June 30, 2023 MODI’IN, Israel and NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update. “We continue to make goo...

Vascular Biogenics (NASDAQ:VBLT – Get Rating) and Sigilon Therapeutics (NASDAQ:SGTX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends. Volatility and Risk Vascular Biogenics has a beta of […]

MODI'IN, Israel and NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) ("VBL"), today announced financial results for the first quarter ended March 31, 2023, and provided a corporate

MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a corporate

Efficient capital deployment in Israel and Singapore designed to support scale-up in key markets Aleph Farms, the first company to grow cultivated steaks directly from non-modified cow cells, today

Efficient capital deployment in Israel and Singapore designed to support scale-up in key marketsREHOVOT, Israel--(BUSINESS WIRE)--#COP26--Aleph Farms, the first company to grow cultivated steaks directly from non-modified cow cells, today announced that it has acquired a manufacturing facility in Modi’in, Israel, an...

The trial of VBL's ofra-vec treatment for ovarian cancer did not meet any of its primary endpoints.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

CCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111) Enrollment in the OVAL Study, a 400 patient...